Andreas Forsland, the founder and CEO of Cognixion, at his company’s Santa Barbara headquarters. The company recently closed a $12 million funding round. (Eric Isaacs photo) Santa Barbara-based Cognixion has received a Breakthrough Device designation from the U.S. Food and Drug Administration, the company announced on May 4, paving the way to get its artificial…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
